CD274 and neoplasm: Prior research has demonstrated that CD8A is associated with the presence of CD8+ T cells which can exert anti‐tumour effects, indicating better immunotherapy outcomes, whereas PD‐L1 is an immune checkpoint protein linked to tumour cells evading immune responses, potentially leading to poor patient prognosis.